Clinicopathologic and molecular biologic analyses for recognizing newly-defined adult lymphoma entities.

用于识别新定义的成人淋巴瘤实体的临床病理学和分子生物学分析。

• 批准号: 14570175
• 负责人: NAKAMURA Shigeo
• 金额: $ 2.24万
• 依托单位: Aichi Cancer Center Research Institute
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2002
• 资助国家: 日本
• 起止时间: 2002 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14570175/
• 关键词: Malignant lymphoma; Disease entity; Diffuse large B-cell lymphoma; CD5; Intravascular pattern; Epstein-Barr virus; Immunodeficiency; Aging

A newly-defined adult lymphoma entities have been analyzed in this study in order to reveal clinicopathologic and biologic profiles of newly-defined adult lymphoma entities, including de novo CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL), intravascular large B-cell lymphoma (IVL), and senile EBC-associated B-cell lymphoproliferative disorder (Senile EBV+ B-LPD). More than 100 cases were registered for constructing the data base in the future case-control clinical trial as the nation-wide multi-center study in CD5+ DLBCL and IVL, respectively. Simultaneously, the prognostic significance of their morphologic and phenotypic variants were clarified, implying their relatively broad spectrum. Senile EBV+ B-LPD were fires described in 2003 by us, sharing several properties with the immunodeficiency-associated lymphoproliferative disorder. This unique disease was assumed to be derived from the immunological deterioration by the aging itself, because most of the patients were more than 60years old with a median of 78 years. We are now concentrating much effort on this newly-recognized disease, which will be more prevalent in the near future, for clarifying the clinical finding and prognosis and developing the new strategies to the treatment and prevention.

本研究分析了新定义的成人淋巴瘤实体，以揭示新定义的成人淋巴瘤实体的临床病理学和生物学特征，包括新发CD 5阳性弥漫性大B细胞淋巴瘤（CD 5 + DLBCL）、血管内大B细胞淋巴瘤（IVL）和老年性EB病毒相关B细胞淋巴增生性疾病（老年性EBV+ B-LPD）。登记了100多例病例，为将来的病例对照临床试验建立数据库，即全国范围内的CD 5 + DLBCL和IVL多中心研究。同时，他们的形态和表型变异的预后意义进行了澄清，这意味着他们的相对广谱。老年EBV+ B-LPD是我们于2003年发现的一种与免疫缺陷相关的淋巴组织增生性疾病有共同特征的疾病。这种独特的疾病被认为是由于衰老本身引起的免疫恶化，因为大多数患者年龄超过60岁，中位数为78岁。目前，我们正致力于这一新认识的疾病，这将在不久的将来更加流行，以澄清临床表现和预后，并制定新的治疗和预防策略。

项目成果

Tsukamoto T, et al.: "Down regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2 : Inverse correlation during progression from gastric/intestinal-mixed to complete intestinal metaplasia"J Ca

Tsukamoto T 等人：“胃转录因子 Sox2 的下调和肠同源盒基因 Cdx1 和 Cdx2 的异位表达：从胃/肠混合到完全肠化生进展过程中的负相关”J Ca

Nomura K, et al.: "Detection of t(11;18)(q21;21) in marginal zone lymphoma of mucosa-assocaited lymphocytic tissue type on paraffin-embedded tissue sections by using fluorescence in situ hybridization."Cancer Genet Cytogenet. 140. 49-54 (2003)

Nomura K 等人：“通过使用荧光原位杂交在石蜡包埋的组织切片上检测粘膜相关淋巴细胞组织类型的边缘区淋巴瘤中的 t(11;18)(q21;21)。”Cancer Genet Cytogenet。

Okabe M, et al.: "API2-MALT1 fusion defines a distinctive clinicopathologic subtype in pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue"Am J Pathol. (in press). (2003)

Okabe M 等人：“API2-MALT1 融合定义了粘膜相关淋巴组织的肺结外边缘区 B 细胞淋巴瘤的独特临床病理亚型”Am J Pathol。

Kojima M, et al.: "Progressive transformation of germinal centers : a clinicopathological study of 42 Japanese patients."Int J Surg Pathol. 11. 101-107 (2003)

Kojima M 等人：“生发中心的进行性转化：42 名日本患者的临床病理学研究。”Int J Surg Pathol。

Kojima M, et al.: "Nodal marginal zone B-cell lymphoma resembling plasmacytoma arising from a plasma cell variant of localized Castlman's disease : a case report."APMIS. 110. 523-527 (2002)

Kojima M 等人：“结节边缘区 B 细胞淋巴瘤类似浆细胞瘤，源自局限性 Castlman 病的浆细胞变体：病例报告。”APMIS。